Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana.

MLA

Diphoko, Thabo, et al. “Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana.” AIDS Research and Human Retroviruses, vol. 34, no. 8, Aug. 2018, pp. 667–71. EBSCOhost, https://doi.org/10.1089/AID.2017.0135.

APA

Diphoko, T., Gaseitsiwe, S., Kasvosve, I., Moyo, S., Okatch, H., Musonda, R., Wainberg, M., Makhema, J., Marlink, R., Novitsky, V., & Essex, M. (2018). Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana. AIDS Research and Human Retroviruses, 34(8), 667–671. https://doi.org/10.1089/AID.2017.0135

Chicago

Diphoko, Thabo, Simani Gaseitsiwe, Ishmael Kasvosve, Sikhulile Moyo, Harriet Okatch, Rosemary Musonda, Mark Wainberg, et al. 2018. “Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana.” AIDS Research and Human Retroviruses 34 (8): 667–71. doi:10.1089/AID.2017.0135.